<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A pathogenic relationship exists between type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Over the last decade, the escalation in <z:mp ids='MP_0002055'>diabetes</z:mp> cases has paralleled the rapid increase in <z:hpo ids='HP_0001513'>obesity</z:hpo> rates, constituting a global health crisis </plain></SENT>
<SENT sid="2" pm="."><plain>Environmental risk factors attributed to the global increase in <z:hpo ids='HP_0001513'>obesity</z:hpo> include the consumption of high-calorie, high-fat foods and inadequate physical activity </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0001261'>Obese</z:mp> individuals may also have a genetic predisposition for <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Both <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001513'>obesity</z:hpo> confer an elevated risk of developing a range of complications and comorbidities, including <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0001297'>stroke</z:hpo>, which can complicate disease management </plain></SENT>
<SENT sid="5" pm="."><plain>This review examines the aetiology of the linkages between <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001513'>obesity</z:hpo> and the range of available therapies </plain></SENT>
<SENT sid="6" pm="."><plain>Recent clinical evidence substantiating the efficacy and safety of incretin-based <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> therapies is analysed, in addition to data on antiobesity therapeutic strategies, such as antiobesity agents, behaviour modification and bariatric surgery </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> control is often accompanied by weight-neutral or modest weight reduction effects with DPP-4 inhibitor treatment (<z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, vildagliptin, saxagliptin) and <z:hpo ids='HP_0001824'>weight loss</z:hpo> with GLP-1 receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> therapy (exenatide, liraglutide) </plain></SENT>
<SENT sid="8" pm="."><plain>Studies of antiobesity agents including orlistat, sibutramine and rimonabant have shown attrition rates of 30-40%, and the long-term effects of these agents remain unknown </plain></SENT>
<SENT sid="9" pm="."><plain>Bariatric surgical procedures commonly performed are laparoscopic adjustable banding of the stomach and the Roux-en-Y gastric bypass, and have produced type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> remission rates of up to 73% </plain></SENT>
<SENT sid="10" pm="."><plain>Therapeutic strategies that integrate glycaemic control and <z:hpo ids='HP_0001824'>weight loss</z:hpo> will assume greater importance as the prevalence of <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001513'>obesity</z:hpo> increase </plain></SENT>
</text></document>